10-QPeriod: Q2 FY2012

ABBOTT LABORATORIES Quarterly Report for Q2 Ended Jun 30, 2012

Filed August 7, 2012For Securities:ABT

Summary

Abbott Laboratories reported solid financial results for the second quarter and first half of 2012, demonstrating consistent revenue growth and operating earnings improvement. Total net sales increased by 2.0% to $9.8 billion for the quarter and 3.3% to $19.3 billion for the first six months, driven by strong performance in the Proprietary Pharmaceutical Products, Nutritional Products, and Diagnostic Products segments. Despite currency headwinds, the company's diversified portfolio and global reach continue to support sales growth. Profitability saw a significant boost, with operating earnings rising by 18.6% to $2.1 billion in the quarter and 19.7% to $3.7 billion for the first six months. This improvement was supported by a higher gross profit margin and effective cost management. The company also continued its strategic focus on product development and pipeline advancement, with significant investment in research and development across its key therapeutic areas. Shareholder returns remained a priority, with continued share repurchases and dividend payments.

Financial Highlights

54 data points
Beta

Revenue

$5.31B

51.7% Gross Margin

Net Income

$1.72B

32.5% Net Margin

EPS (Diluted)

$1.08

Total Assets

$61.86B

Cash & Equivalents

$7.05B

Free Cash Flow

$1.64B

Financial Statements
Beta
Revenue$5.31B
Cost of Revenue$2.37B
Gross Profit$2.75B
SG&A Expenses$1.81B
Operating Expenses$4.75B
Operating Income$564.19M
Interest Expense$83.29M
Net Income$1.72B
EPS (Basic)$1.09
EPS (Diluted)$1.08
Shares Outstanding (Basic)1.57B
Shares Outstanding (Diluted)1.59B

Key Highlights

  • 1Total net sales for the second quarter of 2012 reached $9.8 billion, a 2.0% increase over the prior year, with first six months' sales at $19.3 billion, up 3.3%.
  • 2Operating earnings for the quarter increased by 18.6% to $2.1 billion, and for the first six months by 19.7% to $3.7 billion, indicating improved profitability.
  • 3Proprietary Pharmaceutical Products segment sales grew 4.9% to $4.38 billion for the quarter, and 6.0% to $8.45 billion for the first six months, highlighting continued strength in this key area.
  • 4The company successfully resolved significant legal matters, including the Depakote-related claims, with an $800 million payment made in the quarter towards the settlement.
  • 5Gross profit margin improved to 62.9% in Q2 2012 and 61.8% for the first six months of 2012, up from 59.8% and 58.6% respectively in the prior year, attributed to favorable product mix and cost initiatives.
  • 6Abbott continued to invest in its future with $1.01 billion in R&D for the quarter and $2.02 billion for the first six months, with a focus on pharmaceuticals, biologics, and diagnostics.
  • 7The company actively returned capital to shareholders, repurchasing approximately $1.6 billion in common shares during the first six months of 2012 under its $5 billion authorization.

Frequently Asked Questions

Abbott Laboratories reported total net sales of $9.807 billion for the three months ended June 30, 2012, representing a 2.0% increase compared to $9.616 billion in the same period of 2011. This growth was driven by solid performance across its various business segments.

Abbott reached a resolution for all Depakote-related federal, Medicaid, and consumer protection claims. The company made an $800 million payment in the second quarter of 2012 as part of the total settlement, with the remaining $800 million expected in the second half of 2012. While the payments are material to cash flows, Abbott anticipates its operating cash flow will be sufficient to cover these obligations without significantly impacting liquidity.

The Proprietary Pharmaceutical Products segment showed strong growth, with sales increasing by 4.9% to $4.38 billion for the quarter and 6.0% to $8.45 billion for the first six months. This segment, which includes key products like HUMIRA, continues to be a significant growth driver for the company, supported by ongoing R&D investments and pipeline development.

For the six months ended June 30, 2012, Other, net in cash flow from operating activities included approximately $800 million in payments to settle certain government investigations, notably the Depakote matter. Additionally, the company recorded $110 million in the second quarter for acquired in-process R&D related to the AP214 acquisition. For the first six months of 2011, there was a non-cash impact of $519 million of tax benefits related to favorable resolution of prior tax positions.